en.Wedoany.com Reported - IMG Pharma Co., Ltd. (IMG Pharma), based in Tokyo, Japan, announced that it has reached a definitive agreement to acquire Japanese pharmaceutical manufacturer Matsumoto Pharmaceutical Co., Ltd. This acquisition is a key step for IMG Pharma in strengthening its integrated healthcare platform, aiming to integrate the resources and capabilities of both parties.
IMG Healthcare Group operates an integrated healthcare platform in Asia, providing full life-cycle health management services. As the group's pharmaceutical and product platform, IMG Pharma focuses on translating clinical needs into standardized health products. Founded in 1948, Matsumoto Pharmaceutical holds over 50 drug approvals and more than 30 trademarks, covering fields such as gastroenterology, respiratory, and dermatology, and operates two manufacturing sites in the Kansai region with a total area exceeding 10,000 square meters.
With Kobe as its R&D hub, IMG Pharma is dedicated to research in regenerative medicine and bioactive product development, encompassing technologies like DPSC and iPS cells. This integration combines IMG Pharma's biopharmaceutical capabilities with Matsumoto Pharmaceutical's manufacturing and over-the-counter (OTC) system, forming a multi-layered product structure aimed at developing a scalable health product platform.
Yuki Sakurai, CEO of IMG Pharma, stated: "This agreement is not only an important step in strengthening the IMG Pharma pharmaceutical and product platform but also reflects our broader approach—building a structured system that connects scientific innovation with practical healthcare applications." He added, "By combining R&D and translational capabilities in Kobe with Matsumoto Pharmaceutical’s well-established manufacturing and OTC system, we are creating a more scalable path from clinical care to product-based health solutions."
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
